Literature DB >> 20563826

The wearing-off phenomenon and the use of questionnaires to facilitate its recognition in Parkinson's disease.

Mark Stacy1.   

Abstract

Long-term treatment of Parkinson's disease (PD) with dopaminergic therapy is associated with a re-emergence of PD symptoms, referred to as wearing-off. Signs of wearing-off encompass motor symptoms, such as slowness of movement and stiffness, and non-motor symptoms, including anxiety and fatigue. Both motor and non-motor symptoms impact significantly on the function and quality of life of PD patients. Early detection and management of wearing-off has been shown to improve patient symptoms; however, identification of wearing-off, particularly the non-motor symptoms, is hampered by a lack of patient education, awareness, patient-physician communication, and limited time for evaluation. Several questionnaires have been developed to aid the detection of wearing-off. This review investigates the development and use of the Wearing-Off Questionnaires (WOQ-32, WOQ-19, and WOQ-9), as well as their sensitivity and specificity in identifying wearing-off. The manuscript also provides an overview of the motor and non-motor signs of wearing-off and highlights the available treatment strategies for managing this potentially debilitating phenomenon.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20563826     DOI: 10.1007/s00702-010-0424-5

Source DB:  PubMed          Journal:  J Neural Transm (Vienna)        ISSN: 0300-9564            Impact factor:   3.575


  47 in total

1.  A multicenter trial of ropinirole as adjunct treatment for Parkinson's disease. Ropinirole Study Group.

Authors:  A Lieberman; C W Olanow; K Sethi; P Swanson; C H Waters; S Fahn; H Hurtig; M Yahr
Journal:  Neurology       Date:  1998-10       Impact factor: 9.910

2.  Biochemical variations in the synaptic level of dopamine precede motor fluctuations in Parkinson's disease: PET evidence of increased dopamine turnover.

Authors:  R de la Fuente-Fernández; J Q Lu; V Sossi; S Jivan; M Schulzer; J E Holden; C S Lee; T J Ruth; D B Calne; A J Stoessl
Journal:  Ann Neurol       Date:  2001-03       Impact factor: 10.422

3.  Restless legs syndrome, insomnia and quality of life in patients on maintenance dialysis.

Authors:  Istvan Mucsi; Miklos Zsolt Molnar; Csaba Ambrus; Lilla Szeifert; Agnes Zsofia Kovacs; Rezso Zoller; Szabolcs Barótfi; Adam Remport; Marta Novak
Journal:  Nephrol Dial Transplant       Date:  2005-01-25       Impact factor: 5.992

4.  Entacapone improves motor fluctuations in levodopa-treated Parkinson's disease patients. Parkinson Study Group.

Authors: 
Journal:  Ann Neurol       Date:  1997-11       Impact factor: 10.422

5.  Efficacy and safety of entacapone in Parkinson's disease patients with suboptimal levodopa response: a 6-month randomized placebo-controlled double-blind study in Germany and Austria (Celomen study).

Authors:  W H Poewe; G Deuschl; A Gordin; E-R Kultalahti; M Leinonen
Journal:  Acta Neurol Scand       Date:  2002-04       Impact factor: 3.209

6.  Pramipexole vs levodopa as initial treatment for Parkinson disease: A randomized controlled trial. Parkinson Study Group.

Authors: 
Journal:  JAMA       Date:  2000-10-18       Impact factor: 56.272

7.  Detection of motor and non-motor symptoms of end-of dose wearing-off in Parkinson's disease using a dedicated questionnaire: a Belgian multicenter survey.

Authors:  Patrick Santens; Alain Maertens de Noordhout
Journal:  Acta Neurol Belg       Date:  2006-09       Impact factor: 2.396

8.  Utility of a patient survey in identifying fluctuations in early stage Parkinson's disease.

Authors:  P A Silburn; G D Mellick; B I Vieira; G Danta; R S Boyle; L Herawati
Journal:  J Clin Neurosci       Date:  2008-09-27       Impact factor: 1.961

9.  Entacapone is beneficial in both fluctuating and non-fluctuating patients with Parkinson's disease: a randomised, placebo controlled, double blind, six month study.

Authors:  D J Brooks; H Sagar
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-08       Impact factor: 10.154

10.  Efficacy and tolerability of entacapone in patients with Parkinson's disease treated with levodopa plus a dopamine agonist and experiencing wearing-off motor fluctuations. A randomized, double-blind, multicentre study.

Authors:  G Fénelon; S Giménez-Roldán; J L Montastruc; F Bermejo; F Durif; I Bourdeix; J-J Péré; L Galiano; J Schadrack
Journal:  J Neural Transm (Vienna)       Date:  2003-03       Impact factor: 3.575

View more
  16 in total

1.  Does WOQ-9 help to recognize symptoms of non-motor wearing-off in Parkinson's disease?

Authors:  Martin Bareš; Irena Rektorová; Robert Jech; Kateřina Farníková; Jan Roth; Evžen Růžička; Petr Kaňovský; Ivan Rektor; Tomáš Pavlík; Leona Uhlířová; Jaroslav Vydlák
Journal:  J Neural Transm (Vienna)       Date:  2011-07-17       Impact factor: 3.575

Review 2.  Integrated Approach for Pain Management in Parkinson Disease.

Authors:  Christian Geroin; Marialuisa Gandolfi; Veronica Bruno; Nicola Smania; Michele Tinazzi
Journal:  Curr Neurol Neurosci Rep       Date:  2016-04       Impact factor: 5.081

3.  Non-motor symptoms in a Flanders-Belgian population of 215 Parkinson's disease patients as assessed by the Non-Motor Symptoms Questionnaire.

Authors:  David Crosiers; Barbara Pickut; Jessie Theuns; Peter Paul De Deyn; Christine Van Broeckhoven; Pablo Martinez-Martin; K Ray Chaudhuri; Patrick Cras
Journal:  Am J Neurodegener Dis       Date:  2012-07-23

4.  Parkinson's Disease and Its Management: Part 4: Treatment of Motor Complications.

Authors:  George DeMaagd; Ashok Philip
Journal:  P T       Date:  2015-11

5.  The Most Bothersome Aspects of Off Periods Reported by Individuals with Parkinson's Disease.

Authors:  Lana M Chahine; Briana Edison; Margaret Daeschler; Sneha Mantri; Steven Kahl; Robyn Rapoport; Arina Goyle; Chelle Precht; Catherine Kopil; Connie Marras
Journal:  Mov Disord Clin Pract       Date:  2020-03-05

6.  Impact of insufficient drug efficacy of antiparkinson agents on patient's quality of life: a cross-sectional study.

Authors:  Jun Tsugawa; Rieko Onozawa; Jiro Fukae; Takayasu Mishima; Shinsuke Fujioka; Yoshio Tsuboi
Journal:  BMC Neurol       Date:  2015-07-05       Impact factor: 2.474

7.  BEWARE: Body awareness training in the treatment of wearing-off related anxiety in patients with Parkinson's disease: study protocol for a randomized controlled trial.

Authors:  Ires Ghielen; Odile A van den Heuvel; Cees J T de Goede; Marieke Houniet-de Gier; Emma H Collette; Ingrid A L Burgers-Bots; Sonja Rutten; Gert Kwakkel; Kees Vermunt; Bep van Vliet; Henk W Berendse; Erwin E H van Wegen
Journal:  Trials       Date:  2015-06-23       Impact factor: 2.279

8.  Prevalence of wearing-off and dyskinesia among the patients with Parkinson's disease on levodopa therapy: a multi-center registry survey in mainland China.

Authors:  Wei Chen; Qin Xiao; Ming Shao; Tao Feng; Wei-Guo Liu; Xiao-Guang Luo; Xiao-Chun Chen; An-Mu Xie; Chun-Feng Liu; Zhen-Guo Liu; Yi-Ming Liu; Jian Wang; Sheng-Di Chen
Journal:  Transl Neurodegener       Date:  2014-12-05       Impact factor: 8.014

9.  Recurrent Falls in People with Parkinson's Disease without Cognitive Impairment: Focusing on Modifiable Risk Factors.

Authors:  Lorena R S Almeida; Guilherme T Valença; Nádja N Negreiros; Elen B Pinto; Jamary Oliveira-Filho
Journal:  Parkinsons Dis       Date:  2014-11-23

10.  Objective measurement in routine care of people with Parkinson's disease improves outcomes.

Authors:  Parisa Farzanehfar; Holly Woodrow; Michelle Braybrook; Sarah McGregor; Andrew Evans; Frank Nicklason; Malcolm Horne
Journal:  NPJ Parkinsons Dis       Date:  2018-04-03
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.